Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
03 août 2023 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
14 juin 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
05 juin 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
25 mai 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
12 mai 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m. ET NEWTOWN, Pa., May 12, 2023 (GLOBE NEWSWIRE) --...
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
11 mai 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa., May 11,...
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
08 mai 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
04 mai 2023 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
19 avr. 2023 09h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
06 avr. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...